These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 26872892

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J.
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [Abstract] [Full Text] [Related]

  • 4. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
    Gupta N, Zhang S, Pusalkar S, Plesescu M, Chowdhury S, Hanley MJ, Wang B, Xia C, Zhang X, Venkatakrishnan K, Shepard DR.
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
    Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S.
    Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA.
    Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
    Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K.
    Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
    [Abstract] [Full Text] [Related]

  • 10. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
    Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.
    Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
    [Abstract] [Full Text] [Related]

  • 11. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N, Labotka R, Liu G, Hui AM, Venkatakrishnan K.
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [Abstract] [Full Text] [Related]

  • 12. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M, Gupta N, Hanley MJ, Venkatakrishnan K, Sonnichsen D, Kerstein D, Dorer DJ, Narasimhan N.
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
    Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K.
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R.
    Blood; 2014 Aug 14; 124(7):1047-55. PubMed ID: 24904120
    [Abstract] [Full Text] [Related]

  • 17. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Keirns J.
    Clin Ther; 2013 Mar 14; 35(3):333-41. PubMed ID: 23497763
    [Abstract] [Full Text] [Related]

  • 18. Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
    Qin H, Tan Y, Diao L, Hui AM, Wu Z, Zhou Y, Sun J, Xiang X, Qiu J, Hu W.
    Drugs R D; 2023 Dec 14; 23(4):465-473. PubMed ID: 37934354
    [Abstract] [Full Text] [Related]

  • 19. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
    Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G.
    Epilepsia; 2020 Feb 14; 61(2):267-277. PubMed ID: 32012251
    [Abstract] [Full Text] [Related]

  • 20. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
    Rioux N, Kim A, Nix D, Bowser T, Warmuth M, Smith PG, Schindler J.
    Cancer Chemother Pharmacol; 2019 Jan 14; 83(1):91-96. PubMed ID: 30368584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.